AOP-Wiki

API

All KERs

Showing 2376 to 2400 of 3081 KERs

ID	Upstream Event	Downstream Event	Creation Date	Last Updated	AOPs

2172	1807: Inhibition, Chitobiase	996: Decrease, Digestion of old cuticle	Oct 21, 2020	Oct 21, 2020	1 AOP 359: Chitobiase inhibition leading to mortality
1137	1103: Inhibition, Cyclooxygenase 1 activity	1104: Decreased, Prostaglandin F2alpha concentration, plasma	Nov 29, 2016	Dec 3, 2016	1 AOP 177: Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality
95	79: Inhibition, Cyclooxygenase activity	243: Reduction, Prostaglandin E2 concentration	Nov 29, 2016	Dec 3, 2016	1 AOP 28: Cyclooxygenase inhibition leading reproductive failure
670	79: Inhibition, Cyclooxygenase activity	672: Reduced, Prostaglandin F2alpha synthesis, ovary	Nov 29, 2016	Dec 3, 2016	1 AOP 100: Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior
681	79: Inhibition, Cyclooxygenase activity	681: Decreased, Prostaglandin F2alpha synthesis, ovary	Nov 29, 2016	Dec 3, 2016	1 AOP 101: Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release
686	79: Inhibition, Cyclooxygenase activity	685: Reduced, Prostaglandins, ovary	Nov 29, 2016	Dec 3, 2016	1 AOP 63: Cyclooxygenase inhibition leading to reproductive dysfunction
689	79: Inhibition, Cyclooxygenase activity	687: Reduced, Prostaglandin E2 concentration, hypothalamus	Nov 29, 2016	Dec 3, 2016	2 AOPs 102: Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition 103: Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint
3503	1840: Inhibition, cytochrome oxidase	1825: Increase, Cell death	Mar 5, 2025	Mar 18, 2025	3 AOPs 368: Cytochrome oxidase inhibition leading to increased nasal lesions 573: Inhibition, cytochrome oxidase leads to Increased, pulmonary edema 574: Inhibition, cytochrome oxidase leads to Loss of olfactory function
1878	1609: Inhibition of Cyp17A1 activity	1610: Reduction, DHEA	Apr 10, 2019	Apr 8, 2025	1 AOP 288: Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals)
1879	1609: Inhibition of Cyp17A1 activity	1611: Reduction, androstenedione	Apr 10, 2019	Apr 8, 2025	1 AOP 288: Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals)
1037	1009: Inhibition, Deiodinase 1	1003: Decreased, Triiodothyronine (T3)	Nov 29, 2016	Nov 19, 2025	2 AOPs 157: Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation 158: Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation
1044	1009: Inhibition, Deiodinase 1	1004: Reduced, Posterior swim bladder inflation	Nov 29, 2016	Oct 10, 2022	1 AOP 157: Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation
1045	1009: Inhibition, Deiodinase 1	1007: Reduced, Anterior swim bladder inflation	Nov 29, 2016	Mar 8, 2019	None
1198	1009: Inhibition, Deiodinase 1	1116: Decreased, Triiodothyronine (T3) in tissues	Nov 29, 2016	Dec 3, 2016	1 AOP 189: Type I iodothyronine deiodinase (DIO1) inhibition leading to altered amphibian metamorphosis
1026	1002: Inhibition, Deiodinase 2	1003: Decreased, Triiodothyronine (T3)	Nov 29, 2016	Nov 19, 2025	2 AOPs 155: Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation 156: Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation
1042	1002: Inhibition, Deiodinase 2	1004: Reduced, Posterior swim bladder inflation	Nov 29, 2016	Oct 7, 2022	1 AOP 155: Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation
1043	1002: Inhibition, Deiodinase 2	1007: Reduced, Anterior swim bladder inflation	Nov 29, 2016	Mar 8, 2019	None
1199	1002: Inhibition, Deiodinase 2	1116: Decreased, Triiodothyronine (T3) in tissues	Nov 29, 2016	Nov 19, 2025	1 AOP 190: Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis
3653	1002: Inhibition, Deiodinase 2	2093: Decreased brain T4/T3	Oct 8, 2025	Oct 8, 2025	1 AOP 610: Decreased thyroid hormone levels in the brain regulated via transport, metabolism and TR activation leading to decreased cognition and motor function
1200	1153: Inhibition, Deiodinase 3	1154: Increased, Triiodothyronine (T3) in tissues	Nov 29, 2016	Nov 19, 2025	1 AOP 191: Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosis
1203	1156: Inhibition, Dual oxidase	277: TH synthesis, Decreased	Nov 29, 2016	Dec 3, 2016	1 AOP 193: Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis
3121	2207: inhibition, EKR1/2 signaling pathway	2208: Aberrant, synaptic formation and plasticity	Jan 25, 2024	Jan 25, 2024	1 AOP 522: Estrogen antagonism leading to increased risk of autism-like behavior
597	593: Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel	585: Decreased, Sodium conductance 1	Nov 29, 2016	Dec 3, 2016	1 AOP 95: Ether-a-go-go (ERG) voltage-gated potassium channel inhibition leading to reduced survival
3419	593: Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel	1961: Prolongation of Action Potential	Nov 21, 2024	Nov 21, 2024	1 AOP 555: Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure
1692	1490: Inhibition of fatty acid beta oxidation	1305: Increase, cytosolic fatty acid	Nov 13, 2017	Nov 13, 2017	1 AOP 213: Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH)

Key Event Relationships (KERs)

All KERs